Unit of Internal Medicine, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.
Diabetes Metab Res Rev. 2014 May;30(4):313-22. doi: 10.1002/dmrr.2497.
The FRAX algorithm is a diffuse tool to assess fracture risk, but it has not been clinically applied in European patients with diabetes. We investigated FRAX-estimated fracture risk in patients with type 2 diabetes mellitus (DM), compared with concomitantly enrolled control subjects.
In our multicentric cross-sectional study, we assessed the FRAX scores of 974 DM and 777 control subjects from three Italian diabetes outpatient clinics, and in DM. We tested the association between parameters and complications of the disease and FRAX scores.
DM had significantly lower FRAX-estimated probability of both major osteoporotic fracture (MOF) and hip fracture (HF) than control subjects (6.35 ± 5.07% versus 7.75 ± 6.93%, p < 0.001, and 2.17 ± 3.07% versus 2.91 ± 4.56%, p = 0.023, respectively). When grouping by gender, such differences were found only in men. In DM, the frequency of previous fracture was higher than in control subjects (29.88% versus 20.46%, p < 0.001). In diabetic patients, age, sex, body mass index, HbA1c and hypoglycaemia are significantly associated with FRAX scores; gender-specific regression models differed. Among DM, the tree-based regression (classification and regression tree (CART)) analysis identified groups of patients with different mean FRAX scores. In female DM aged > 65 years with or without obesity, MOF > 20% was found in 5.66% and 13.53% and H > 3% in 40.57% and 63.91% of patients, respectively.
Patients with DM had mean FRAX scores lower than control subjects, despite the higher number of previous fractures. Some features and complications of DM did associate with FRAX scores. Among DM patients, the CART analysis identified subgroups with higher FRAX scores. However, despite its potential utility, concerns still remain for using FRAX in DM patients.
FRAX 算法是一种评估骨折风险的广泛工具,但尚未在欧洲糖尿病患者中得到临床应用。我们研究了 FRAX 估计的 2 型糖尿病(DM)患者的骨折风险,并与同时纳入的对照组进行了比较。
在我们的多中心横断面研究中,我们评估了来自意大利三个糖尿病门诊诊所的 974 例 DM 和 777 例对照受试者的 FRAX 评分,以及 DM 患者的 FRAX 评分。我们测试了疾病参数和并发症与 FRAX 评分之间的关系。
DM 患者的主要骨质疏松性骨折(MOF)和髋部骨折(HF)的 FRAX 估计概率明显低于对照组(6.35±5.07%比 7.75±6.93%,p<0.001;2.17±3.07%比 2.91±4.56%,p=0.023)。按性别分组时,仅在男性中发现了这种差异。在 DM 患者中,既往骨折的频率高于对照组(29.88%比 20.46%,p<0.001)。在糖尿病患者中,年龄、性别、体重指数、HbA1c 和低血糖与 FRAX 评分显著相关;性别特异性回归模型不同。在 DM 患者中,基于树的回归(分类和回归树(CART))分析确定了不同 FRAX 评分的患者组。在年龄>65 岁且有或无肥胖的女性 DM 患者中,MOF>20%分别在 5.66%和 13.53%的患者中发现,HF>3%分别在 40.57%和 63.91%的患者中发现。
尽管 DM 患者既往骨折次数较多,但他们的平均 FRAX 评分低于对照组。DM 的某些特征和并发症与 FRAX 评分相关。在 DM 患者中,CART 分析确定了具有较高 FRAX 评分的亚组。然而,尽管其具有潜在的效用,但在 DM 患者中使用 FRAX 仍存在一些担忧。